ClinicalTrials.gg
CompletedNCT03394950Updated Jun 2, 2021

Butyphthalide in Combination With Recombinant Tissue Plasminogen Activator for Acute Ischemic Stroke

A Phase 4 interventional study of Butyphthalide combined with rtPA and rtPA in Stroke, Ischemic, sponsored by Hui-Sheng Chen. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-02.

Sponsored by Hui-Sheng Chen · Phase 4, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 753 studies in Ischemic Stroke with a site in China — 380 open to participants now, 399 under way, 78 of them phase 3. Ischemic Stroke · China.

Enrollment
391st of 565
120 · median 270
Started
2018
with 39 others
Phase 4
70 of 753
31 open now
Registered
100th of 753
by date

Among the 753 studies in Ischemic Stroke with a site in China, this one is the 391st largest by enrollment of the 565 interventional ones that give a count, is one of 40 that started in 2018, is one of 70 in phase 4, and was the 100th registered.

Ischemic Stroke

2,625 studies on the registry are indexed under Ischemic Stroke; 982 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

380 of the 753 studies in Ischemic Stroke with a site in China are open now. Recruiting first, the newest first:

375 more — sign in →

All 380 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 402 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 753 studies in Ischemic Stroke with a site in China, or all of them as a file.
02

Study summary

Acute ischemic stroke (AIS) is the most common type of stroke, which has high rate of morbidity, mortality and disability. A large number of studies have confirmed that the thrombolytic therapy can effectively open blood vessels and improve the functional prognosis of acute ischemic stroke. Therefore, all guidelines recommend giving thrombolysis treatment to acute ischemic stroke patients within 4.5 hours of onset. However, about 1/3 patients receiving thrombolysis will have good prognosis, while a large number of patients will still be disabled and even dead. How to improve the neurofunctional prognosis of thrombolytic patients has been a hot topic in the world.

Butyl phthalide is type I chemical drugs. Some multicenter randomized, double-blind, placebo-controlled clinical trials have showed that acute ischemic stroke patients taking butyl phthalide has better lateral branch circulation and living ability score than patients taking placebo. Besides, butyl phthalide treatment is safe. The animal experiment indicated that buphthalein could significantly improve secondary side branch circulation, recover the microarterial diameter of the soft meninges in the ischemic region and increase the blood flow rate.

Based on the discussion, we assume that: giving butyl phthalide to patients with acute ischemic stroke in advance, might promote and improve the formation of collateral circulation to freeze ischemia penumbra. Based on this hypothesis, we would like to explore the efficacy and safety of butyl phthalide combined with rtPA thrombolysis in the treatment of acute ischemic stroke.

03

Conditions studied

  • Stroke, Ischemic

Browse trials for

Keywords

  • thrombolysis
  • Butyphthalide
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age >18 years;
  2. Diagnosis of anterior circulation infarct;
  3. First stroke onset or past stroke without obvious neurological deficit (mRS≤1);
  4. Time from onset to treatment ≤4.5 hours;
  5. SBP/DBP ≤ 180/110mmHg;
  6. No hemorrhagic imaging changes showed in CT;
  7. Signed by patient self or legally authorized representatives.

Exclusion criteria

Exclusion Criteria:

  1. History of stroke within 3 months;
  2. History of intracranial hemorrhage;
  3. Suspected subarachnoid hemorrhage;
  4. Intracranial tumour, vascular malformation or arterial aneurysm;
  5. Major surgery within 1 month;
  6. Systolic pressure ≥180 mmHg or diastolic pressure ≥110 mmHg;
  7. count \< 100×109/L;
  8. Heparin therapy or oral anticoagulation therapy within 48 hours;
  9. Severe disease with a of less than 3 months;
  10. Blood glucose \< 50 mg/dL (2.7mmol/L);
  11. Patients who have received any other drug or device within 3 months;
  12. Researchers consider patients inappropriate to participate in the registry. -
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    rtPA combined with Butyphthalide

    Intravenous treatment with 25mg butyphthalide, followed by intravenous throbolysis with 0.9mg/kg rtPA. Next day, intravenous treatment with 25mg butyphthalide 2 times/day for 14 days, followed by oral butyphthalide capsule (0.2g 3 times/day) to 90 days after thrombolysis. Other treatments were done according to guidelines.

    Drug: Butyphthalide combined with rtPA

  • Active comparator
    rtPA compared with placebo

    Intravenous treatment with placebo injection, followed by intravenous throbolysis with 0.9mg/kg rtPA. Next day, intravenous treatment with placebo injection 2 times/day for 14 days, followed by oral placebo capsule (3 times/day) to 90 days after thrombolysis. Other treatments were done according to guidelines.

    Drug: rtPA

Interventions

  • DrugButyphthalide combined with rtPA

    Intravenous treatment with 25mg butyphthalide, followed by intravenous throbolysis with 0.9mg/kg rtPA. Next day, intravenous treatment with 25mg butyphthalide 2 times/day for 14 days, followed by oral butyphthalide capsule (0.2g 3 times/day) to 90 days after thrombolysis. Other treatments were done according to guidelines.

  • DrugTissue Plasminogen ActivatorStudies of Tissue Plasminogen ActivatorTissue Plasminogen Activator pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Intravenous thrombolysi with 0.9mg/kg rtPA, followed by other treatments according to guidelines

06

What researchers measure

Primary outcomes

  1. Percentage of mRS score (0-2) (90 days)

    Percentage of mRS score (0-2) at 90 days

    Time frame: 90 days

07

Study locations

1 site
  • General Hospital of ShenYang Military Region
    ShenYang, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2018 to primary completion in May 2021, 36 months.

Of 76 non-industry phase 4 interventional studies under Ischemic Stroke, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 42. This study's 36 months is above that.

Counting every sponsor, half of 85 studies reached it within 31 months; a quarter within 24 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2018
First posted
Jan 9, 2018
StartActual
May 25, 2018
Primary completionActual
May 29, 2021
CompletionActual
May 29, 2021
Last update
Jun 2, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03394950
Lead sponsor
Hui-Sheng Chen
Responsible party
Hui-Sheng Chen (Professor, General Hospital of Shenyang Military Region) — Sponsor-investigator
First posted
Jan 9, 2018
Start date
May 25, 2018
Primary completion
May 29, 2021
Completion
May 29, 2021
Last update
Jun 2, 2021

Study contacts

chen huisheng, doctor
study director · General Hospital of Shenyang Military Region

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion